ClinicalTrials.gov
ClinicalTrials.gov Menu

ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02973802
Recruitment Status : Completed
First Posted : November 25, 2016
Last Update Posted : February 20, 2018
Sponsor:
Collaborators:
Quintiles, Inc.
European Commission
Information provided by (Responsible Party):
Apitope International NV

Brief Summary:
Phase 1 study to assess the safety and biological activity of ATX-GD-59 in patients with Graves Disease not currently treated with anti-thyroid therapy. This will be an open label dose titration involving injections on 10 occasions, each two weeks apart. After dosing is complete there will be a 12 week follow up period. Blood samples will be drawn throughout the study to monitor safety and the body's response to the injections. Thyroid function will be measured throughout the trial to monitor Graves disease progression.

Condition or disease Intervention/treatment Phase
Graves Disease Biological: ATX-GD-59 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Proof of Principle Study of ATX-GD-59 in Male and Female Subjects With Graves' Disease Not Currently Treated With Anti-thyroid Therapy: An Open Label Study, With an Upward Titration Over Five Dose Levels Administered by Intradermal Injection
Actual Study Start Date : September 2016
Actual Primary Completion Date : February 14, 2018
Actual Study Completion Date : February 14, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Thyroid Diseases

Arm Intervention/treatment
Experimental: ATX-GD-59 treatment
An upward titration over five dose levels (25, 50, 100, 400 and 800 micrograms) followed by 5 doses of 800 micrograms of ATXD-GD-59 will be administered two weeks apart by intradermal injection.
Biological: ATX-GD-59
Disease specific immune modulating treatment for Graves Disease




Primary Outcome Measures :
  1. Occurrence of treatment emergent Adverse Events (AE), Serious Adverse Events, and laboratory abnormalities up to week 22 compared to baseline. [ Time Frame: 22 weeks ]

Secondary Outcome Measures :
  1. Change in serum anti-TSHR antibodies from baseline to week 30. [ Time Frame: 30 weeks ]
  2. Change in serum free triiodothyronine (T3) from baseline to week 30. [ Time Frame: 30 weeks ]
  3. Change in serum free thyroxine (T4) from baseline to week 30. [ Time Frame: 30 weeks ]
  4. Change in serum thyroid stimulating hormone (TSH) from baseline to week 30. [ Time Frame: 30 weeks ]
  5. Change from baseline in peripheral blood mononuclear cell (PBMC) T cell activity [ Time Frame: weeks 0, 18 and 22 ]
  6. Change from baseline in IL-10 mRNA expression in PBMCs [ Time Frame: weeks 0, 18 and 22 ]
  7. Change from baseline in biomarker signature of PBMC cells [ Time Frame: weeks 0, 18 and 22 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. A diagnosis of Graves' disease as assessed by a physician from clinical and laboratory findings and not receiving anti-thyroid therapy.
  2. Quantifiable levels of TSHR antibodies.
  3. Raised levels of free T3 and/or free T4 (not exceeding 15 pmol/L and 35 pmol/L respectively) including undetectable levels of thyroid stimulating hormone.
  4. HLA-DRB1*15, HLA DRB1*03 and or HLA DRB1*04 positive.
  5. Age 18 - 65 years inclusive at the time of informed consent.
  6. The subject must be willing and able to give written informed consent and must be willing to comply with protocol assessments/procedures.
  7. Male subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control for the duration of the study until at least 90 days after the last dose of ATX-GD-59.
  8. Female subjects of child bearing potential must: - neither be pregnant nor breast-feeding, nor attempting to conceive, and - use a highly effective method of contraception as defined below, throughout the entire duration of the study and for at least 90 days after the last dose of ATX-GD-59. A serum pregnancy test will be performed at the screening visit in women of child bearing potential. Thereafter urine pregnancy tests will be performed. A positive result will exclude the woman from the study immediately. A highly effective method of contraception is defined as those which result in a low failure rate when used consistently and correctly such as implants, injectable, combined oral contraceptives, some Intrauterine Devices (IUDs), unless post-menopausal or surgically sterilized. Barrier forms of contraception are considered appropriate when used in combination with one of the above methods.

Exclusion Criteria:

  1. Subjects who are pregnant or breastfeeding and/or subjects in the post-partum period.
  2. A known history of, or hypersensitivity reactions that in the opinion of the investigator would exclude the subjects' participation in the study.
  3. Treatment with any Anti-Thyroid Drugs eg carbimazole within the previous 3 months prior to Study Day 1.
  4. Previous treatment with radioiodine or (partial or complete) thyroidectomy.
  5. Signs of moderate or severe orbitopathy including optic nerve compression requiring steroids and/or a clinical activity score >3.
  6. Large and compressive goitres causing localised symptoms such as difficulty swallowing or breathing.
  7. Treatment with steroids (administered via the oral and/or parenteral routes) or adrenocorticotropic hormone with the exception of inhaled steroids within the three months prior to Study Day 1.
  8. Symptoms and signs of thyroid storm such as confusion, pyrexia with no other cause than hyperthyroidism.
  9. Significant cardiac disease and/or atrial fibrillation that would require urgent treatment of thyrotoxicosis.
  10. Prior treatment with biological or peptide-based therapeutics including rituximab.
  11. Prior use of disease related T cell vaccine or peptide-tolerising agent to treat Graves' disease.
  12. Detectable levels of antibodies in plasma specific for any of the peptides within ATX-GD-59 at the screening visit.
  13. A history of significant drug allergies.
  14. The use of any investigational drug, or participation in any Clinical Trial within three months prior to Study Day 1.
  15. Treatment with any cytokine or anti-cytokine therapy within three months prior to Study Day 1.
  16. Inadequate liver function, defined by a total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase > 3 times the upper limit of the normal values at Screening visit. 17. Subject with any significant medical illness or psychiatric condition that in the opinion of the Investigator, would preclude participation in the study or impair the ability to give informed consent; any other clinically apparent autoimmune disease.

18. Clinically significant illness, as determined by the investigator, within 4 weeks prior to the first dose (Study Day 1) of ATX-GD-59.

19. Known history of active or chronic infectious disease or any disease which compromises immune function (e.g. HIV+, HTLV-1, Lyme disease, Latent or active TB, Hepatitis).

20. Major surgery in previous four weeks before screening visit. 21. Known osteoporosis or metabolic bone disease.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02973802


Locations
United Kingdom
Queen Elizabeth Hospital
Birmingham, United Kingdom
University Hospital of Wales
Cardiff, United Kingdom
Royal Devon and Exeter Hospital
Exeter, United Kingdom
St James's University Hospital
Leeds, United Kingdom, LS9 7TF
Hammersmith Hospital
London, United Kingdom, W12 0HS
Kings College Hospital
London, United Kingdom
The Christie
Manchester, United Kingdom
Royal Victoria Infirmary
Newcastle, United Kingdom
Sponsors and Collaborators
Apitope International NV
Quintiles, Inc.
European Commission
Investigators
Principal Investigator: Simon HS Pearce Royal Victoria Infirmary

Additional Information:
Responsible Party: Apitope International NV
ClinicalTrials.gov Identifier: NCT02973802     History of Changes
Other Study ID Numbers: ATX-GD-59-001
First Posted: November 25, 2016    Key Record Dates
Last Update Posted: February 20, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Apitope International NV:
Graves Disease
Phase 1

Additional relevant MeSH terms:
Graves Disease
Exophthalmos
Orbital Diseases
Eye Diseases
Goiter
Thyroid Diseases
Endocrine System Diseases
Hyperthyroidism
Autoimmune Diseases
Immune System Diseases